Motpoly XR indications expanded to include generalized tonic clonic seizures

FDA approved Motpoly XR (lacosamide) for adjunctive treatment of primary generalized tonic-clonic seizures in adults and pediatric patients weighing ≥50 kg. Previously, the drug was approved only for treatment of partial-onset seizures in adults and pediatric patients ≥50 kg.